Nutrition Research and Practice

The Korean Nutrition Society (한국영양학회)
권호 표지
DOI QR코드

DOI QR Code

Role of n-3 long-chain polyunsaturated fatty acids in human nutrition and health: review of recent studies and recommendations

  • Received : 2020.04.06
  • Accepted : 2020.06.19
  • Published : 2021.04.01
Download PDF
⟨ Previous Next ⟩

Abstract

Long-chain (LC) n-3 polyunsaturated fatty acids (n-3 PUFAs), in particular docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), are nutrients involved in many metabolic and physiological processes, and are referred to as n-3 LCPUFA. They have been extensively studied for their effects in human nutrition and health. This paper provides an overview on metabolism, sources, dietary intake, and status of n-3 LCPUFA. A summary of the dietary recommendations for n-3 LCPUFAs for different age groups as well as specific physiological conditions is provided. Evidence for n-3 LCPUFA in cardiovascular diseases, including new studies, is reviewed. Expert recommendations generally support a beneficial effect of n-3 LCPUFA on cardiovascular health and recommend a daily intake of 500 mg as DHA and EPA, or 1-2 servings of fish per week. The role of n-3 LCPUFA on brain health, in particular neurodegenerative disorders and depression, is reviewed. The evidence for beneficial effects of n-3 LCPUFA on neurodegenerative disorders is non-conclusive despite mechanistic support and observational data. Hence, no definite n-3 LCPUFA expert recommendations are made. Data for the beneficial effect of n-3 LCPUFA on depression are generally compelling. Expert recommendations have been established: 200-300 mg/day for depression; up to 1-2 g/day for major depressive disorder. Recent studies support a beneficial role of n-3 LCPUFAs in reducing the risk for premature birth, with a daily intake of 600-800 mg of DHA during pregnancy. Finally, international experts recently reviewed the scientific evidence on DHA and arachidonic acid (ARA) in infant nutrition and concluded that the totality of data support that infant and follow-on formulas should provide both DHA and ARA at levels similar to those in breast milk. In conclusion, the available scientific data support that dietary recommendations for n-3 LCPUFA should be established for the general population and for subjects with specific physiological conditions.

Keywords

References

  1. World Health Organization (WHO). Global Status Report on Noncommunicable Diseases 2014. Geneva: WHO; 2014.
  2. World Health Organization (WHO). Global Action Plan for the Prevention and Control of NCDs 2013-2020 [Internet]. Geneva: WHO; 2013 [cited 2020 April 5]. Available from: https://www.who.int/nmh/publications/ncd-action-plan/en/.
  3. Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol 2011;58:2047-67. https://doi.org/10.1016/j.jacc.2011.06.063
  4. Sinn N, Milte CM, Street SJ, Buckley JD, Coates AM, Petkov J, Howe PR. Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: a 6-month randomised controlled trial. Br J Nutr 2012;107:1682-93. https://doi.org/10.1017/S0007114511004788
  5. Middleton P, Gomersall JC, Gould JF, Shepherd E, Olsen SF, Makrides M. Omega-3 fatty acid addition during pregnancy. Cochrane Database Syst Rev 2018;11:CD003402.
  6. Lapillonne A. Enteral and parenteral lipid requirements of preterm infants. World Rev Nutr Diet 2014;110:82-98. https://doi.org/10.1159/000358460
  7. Koletzko B, Bergmann K, Brenna JT, Calder PC, Campoy C, Clandinin MT, Colombo J, Daly M, Decsi T, Demmelmair H, Domellof M, FidlerMis N, Gonzalez-Casanova I, van Goudoever JB, Hadjipanayis A, Hernell O, Lapillonne A, Mader S, Martin CR, Matthaus V, Ramakrishan U, Smuts CM, Strain SJ, Tanjung C, Tounian P, Carlson SE. Should formula for infants provide arachidonic acid along with DHA? A position paper of the European Academy of Paediatrics and the Child Health Foundation. Am J Clin Nutr 2020;111:10-6.
  8. Goyens PL, Spilker ME, Zock PL, Katan MB, Mensink RP. Conversion of alpha-linolenic acid in humans is influenced by the absolute amounts of alpha-linolenic acid and linoleic acid in the diet and not by their ratio. Am J Clin Nutr 2006;84:44-53. https://doi.org/10.1093/ajcn/84.1.44
  9. Kinsella JE, Lokesh B, Broughton S, Whelan J. Dietary polyunsaturated fatty acids and eicosanoids: potential effects on the modulation of inflammatory and immune cells: an overview. Nutrition 1990;6:24-44.
  10. Clandinin MT. Brain development and assessing the supply of polyunsaturated fatty acid. Lipids 1999;34:131-7. https://doi.org/10.1007/s11745-999-0347-y
  11. Salem N Jr, Wegher B, Mena P, Uauy R. Arachidonic and docosahexaenoic acids are biosynthesized from their 18-carbon precursors in human infants. Proc Natl Acad Sci U S A 1996;93:49-54. https://doi.org/10.1073/pnas.93.1.49
  12. Schaeffer L, Gohlke H, Müller M, Heid IM, Palmer LJ, Kompauer I, Demmelmair H, Illig T, Koletzko B, Heinrich J. Common genetic variants of the FADS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids. Hum Mol Genet 2006;15:1745-56. https://doi.org/10.1093/hmg/ddl117
  13. Micha R, Khatibzadeh S, Shi P, Fahimi S, Lim S, Andrews KG, Engell RE, Powles J, Ezzati M, Mozaffarian DGlobal Burden of Diseases Nutrition and Chronic Diseases Expert Group NutriCoDE. Global, regional, and national consumption levels of dietary fats and oils in 1990 and 2010: a systematic analysis including 266 country-specific nutrition surveys. BMJ 2014;348:g2272. https://doi.org/10.1136/bmj.g2272
  14. Patterson AC, Hogg RC, Kishi DM, Stark KD. Biomarker and dietary validation of a Canadian food frequency questionnaire to measure eicosapentaenoic and docosahexaenoic acid intakes from whole food, functional food, and nutraceutical sources. J Acad Nutr Diet 2012;112:1005-14. https://doi.org/10.1016/j.jand.2012.03.030
  15. Fratesi JA, Hogg RC, Young-Newton GS, Patterson AC, Charkhzarin P, Block Thomas K, Sharratt MT, Stark KD. Direct quantitation of omega-3 fatty acid intake of Canadian residents of a long-term care facility. Appl Physiol Nutr Metab 2009;34:1-9.
  16. Patterson AC, Metherel AH, Hanning RM, Stark KD. The percentage of DHA in erythrocytes can detect non-adherence to advice to increase EPA and DHA intakes. Br J Nutr 2014;111:270-8. https://doi.org/10.1017/S0007114513002225
  17. Block RC, Harris WS, Pottala JV. Determinants of blood cell omega-3 fatty acid content. Open Biomark J 2008;1:1-6. https://doi.org/10.2174/1875318300801010001
  18. Flock MR, Skulas-Ray AC, Harris WS, Etherton TD, Fleming JA, Kris-Etherton PM. Determinants of erythrocyte omega-3 fatty acid content in response to fish oil supplementation: a dose-response randomized controlled trial. J Am Heart Assoc 2013;2:e000513. https://doi.org/10.1161/JAHA.113.000513
  19. Stark KD, Beblo S, Murthy M, Whitty JE, Buda-Abela M, Janisse J, Rockett H, Martier SS, Sokol RJ, Hannigan JH, Salem N Jr. Alcohol consumption in pregnant, black women is associated with decreased plasma and erythrocyte docosahexaenoic acid. Alcohol Clin Exp Res 2005;29:130-40. https://doi.org/10.1097/01.ALC.0000150013.65416.06
  20. Harris WS, Pottala JV, Lacey SM, Vasan RS, Larson MG, Robins SJ. Clinical correlates and heritability of erythrocyte eicosapentaenoic and docosahexaenoic acid content in the Framingham Heart Study. Atherosclerosis 2012;225:425-31. https://doi.org/10.1016/j.atherosclerosis.2012.05.030
  21. Crowe FL, Skeaff CM, Green TJ, Gray AR. Serum n-3 long-chain PUFA differ by sex and age in a population-based survey of New Zealand adolescents and adults. Br J Nutr 2008;99:168-74. https://doi.org/10.1017/S000711450779387X
  22. Siscovick DS, Raghunathan TE, King I, Weinmann S, Wicklund KG, Albright J, Bovbjerg V, Arbogast P, Smith H, Kushi LH, Cobb LA, Copass MK, Psaty BM, Lemaitre R, Retzlaff B, Childs M, Knopp RH. Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. JAMA 1995;274:1363-7. https://doi.org/10.1001/jama.1995.03530170043030
  23. Albert CM, Campos H, Stampfer MJ, Ridker PM, Manson JE, Willett WC, Ma J. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med 2002;346:1113-8. https://doi.org/10.1056/NEJMoa012918
  24. Schaefer EJ, Bongard V, Beiser AS, Lamon-Fava S, Robins SJ, Au R, Tucker KL, Kyle DJ, Wilson PW, Wolf PA. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch Neurol 2006;63:1545-50. https://doi.org/10.1001/archneur.63.11.1545
  25. Stark KD, Van Elswyk ME, Higgins MR, Weatherford CA, Salem N Jr. Global survey of the omega-3 fatty acids, docosahexaenoic acid and eicosapentaenoic acid in the blood stream of healthy adults. Prog Lipid Res 2016;63:132-52. https://doi.org/10.1016/j.plipres.2016.05.001
  26. Food and Agriculture Organization of the United Nations. FAO Fats and Fatty Acids in Human Nutrition. Report of an Expert Consultation. Rome: Food and Agriculture Organization of the United Nations; 2010.
  27. EFSA Panel on Dietetic Products, Nutrition, and Allergies (NDA). Scientific Opinion on Dietary Reference Values for fats, including saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, trans fatty acids, and cholesterol. EFSA J 2010;8:1461.
  28. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on the Tolerable Upper Intake Level of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA). EFSA J 2012;10:2815.
  29. Institute of Medicine (US). Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: National Academy Press; 2005.
  30. U.S. Food and Drug Administration (FDA). Advice about Eating Fish [Internet]. Silver Spring: FDA; 2020 [cited 2020 April 5]. Available from: https://www.fda.gov/food/consumers/advice-about-eating-fish.
  31. U.S. Food and Drug Administration (FDA). Qualified Health Claims: Letters of Enforcement Discretion [Internet]. Silver Spring: FDA; 2020 [cited 2020 April 5]. Available from: https://www.fda.gov/food/food-labeling-nutrition/qualified-health-claims-letters-enforcement-discretion.
  32. U.S. Department of Health and Human Services; U.S. Department of Agriculture. 2015-2020 Dietary Guidelines for Americans. 8th ed. Washington, D.C.: U.S. Government Printing Office; 2015.
  33. US Department of Agriculture; US Department of Health and Human Services. Scientific Report of the 2015 Dietary Guidelines Advisory Committee. Washington, D.C.: U.S. Government Printing Office; 2015.
  34. National Health and Medical Research Council (AU). Nutrient Reference Values for Australia and New Zealand including Recommended Dietary Intakes (version 1.2). Canberra: National Health and Medical Research Council (AU); 2017.
  35. Dolecek TA. Epidemiological evidence of relationships between dietary polyunsaturated fatty acids and mortality in the multiple risk factor intervention trial. Proc Soc Exp Biol Med 1992;200:177-82. https://doi.org/10.3181/00379727-200-43413
  36. Iso H, Rexrode KM, Stampfer MJ, Manson JE, Colditz GA, Speizer FE, Hennekens CH, Willett WC. Intake of fish and omega-3 fatty acids and risk of stroke in women. JAMA 2001;285:304-12. https://doi.org/10.1001/jama.285.3.304
  37. Department of Health and Human Services, U.S. Food and Drug Administration. Substances affirmed as generally recognized as safe: menhaden oil [Internet]. College Park: Office of the Federal Register; 2005 [cited 2020 April 5]. https://www.federalregister.gov/documents/2005/03/23/05-5641/substances-affirmed-as-generally-recognized-as-safe-menhaden-oil.
  38. French Agency for Food, Environmental and Occupational Health Safety (ANSES). Update of the Recommended Nutritional Intake for Fatty Acids. Collective Expert Report [Internet]. Maisons-Alfort: ANSES; 2011 [cited 2020 April 5]. Available from: https://www.anses.fr/en/system/files/NUT2006sa0359Ra.pdf.
  39. Beaufrère B, Bresson JL, Briend A, Ghisolfi J, Goulet A, Putet G, Rieu D, Turck D, Vidailhet M. In: Martin, A, edtior. Recommended Nutritional Intakes for the French Population. Paris: Ed Tec et Doc.; 2001.
  40. Mozaffarian D, Wu JH. (n-3) fatty acids and cardiovascular health: are effects of EPA and DHA shared or complementary? J Nutr 2012;142:614S-625S. https://doi.org/10.3945/jn.111.149633
  41. Kris-Etherton PM, Harris WS, Appel LJNutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002;106:2747-57. https://doi.org/10.1161/01.CIR.0000038493.65177.94
  42. Siscovick DS, Barringer TA, Fretts AM, Wu JH, Lichtenstein AH, Costello RB, Kris-Etherton PM, Jacobson TA, Engler MB, Alger HM, Appel LJ, Mozaffarian DAmerican Heart Association Nutrition Committee of the Council on Lifestyle and Cardiometabolic HealthCouncil on Epidemiology and PreventionCouncil on Cardiovascular Disease in the YoungCouncil on Cardiovascular and Stroke NursingCouncil on Clinical Cardiology. Omega-3 polyunsaturated fatty acid (fish oil) supplementation and the prevention of clinical cardiovascular disease: a science advisory from the American Heart Association. Circulation 2017;135:e867-84. https://doi.org/10.1161/CIR.0000000000000482
  43. Skulas-Ray AC, Wilson PWF, Harris WS, Brinton EA, Kris-Etherton PM, Richter CK, Jacobson TA, Engler MB, Miller M, Robinson JG, Blum CB, Rodriguez-Leyva D, de Ferranti SD, Welty FKAmerican Heart Association Council on Arteriosclerosis, Thrombosis and Vascular BiologyCouncil on Lifestyle and Cardiometabolic HealthCardiovascular Disease in the YoungCouncil on Cardiovascular and Stroke NursingCouncil on Clinical Cardiology. Omega-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association. Circulation 2019;140:e673-91.
  44. Aung T, Halsey J, Kromhout D, Gerstein HC, Marchioli R, Tavazzi L, Geleijnse JM, Rauch B, Ness A, Galan P, Chew EY, Bosch J, Collins R, Lewington S, Armitage J, Clarke ROmega-3 Treatment Trialists' Collaboration. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77,917 individuals. JAMA Cardiol 2018;3:225-34. https://doi.org/10.1001/jamacardio.2017.5205
  45. Abdelhamid AS, Brown TJ, Brainard JS, Biswas P, Thorpe GC, Moore HJ, Deane KH, AlAbdulghafoor FK, Summerbell CD, Worthington HV, Song F, Hooper L. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 2018;7:CD003177.
  46. Arca M, Borghi C, Pontremoli R, De Ferrari GM, Colivicchi F, Desideri G, Temporelli PL. Hypertriglyceridemia and omega-3 fatty acids: Their often overlooked role in cardiovascular disease prevention. Nutr Metab Cardiovasc Dis 2018;28:197-205. https://doi.org/10.1016/j.numecd.2017.11.001
  47. Rimm EB, Appel LJ, Chiuve SE, Djousse L, Engler MB, Kris-Etherton PM, Mozaffarian D, Siscovick DS, Lichtenstein AHAmerican Heart Association Nutrition Committee of the Council on Lifestyle and Cardiometabolic HealthCouncil on Epidemiology and PreventionCouncil on Cardiovascular Disease in the YoungCouncil on Cardiovascular and Stroke NursingCouncil on Clinical Cardiology. Seafood longchain n-3 polyunsaturated fatty acids and cardiovascular disease: a science advisory from the American Heart Association. Circulation 2018;138:e35-47. https://doi.org/10.1161/CIR.0000000000000574
  48. Pizzini A, Lunger L, Sonnweber T, Weiss G, Tancevski I. The role of omega-3 fatty acids in the setting of coronary artery disease and COPD: a review. Nutrients 2018;10:1864. https://doi.org/10.3390/nu10121864
  49. Wen YT, Dai JH, Gao Q. Effects of omega-3 fatty acid on major cardiovascular events and mortality in patients with coronary heart disease: a meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis 2014;24:470-5. https://doi.org/10.1016/j.numecd.2013.12.004
  50. Kwak SM, Myung SK, Lee YJ, Seo HGKorean Meta-analysis Study Group. Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials. Arch Intern Med 2012;172:686-94. https://doi.org/10.1001/archinternmed.2012.262
  51. Nestel P, Clifton P, Colquhoun D, Noakes M, Mori TA, Sullivan D, Thomas B. Indications for omega-3 long chain polyunsaturated fatty acid in the prevention and treatment of cardiovascular disease. Heart Lung Circ 2015;24:769-79. https://doi.org/10.1016/j.hlc.2015.03.020
  52. Meyer BJ, Groot RH. Effects of omega-3 long chain polyunsaturated fatty acid supplementation on cardiovascular mortality: the importance of the dose of DHA. Nutrients 2017;9:1305. https://doi.org/10.3390/nu9121305
  53. Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, Gibson H, Albert CM, Gordon D, Copeland T, D'Agostino D, Friedenberg G, Ridge C, Bubes V, Giovannucci EL, Willett WC, Buring JEVITAL Research Group. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. N Engl J Med 2019;380:23-32. https://doi.org/10.1056/NEJMoa1811403
  54. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CMREDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 2019;380:11-22. https://doi.org/10.1056/NEJMoa1812792
  55. Uauy R, Hoffman DR, Peirano P, Birch DG, Birch EE. Essential fatty acids in visual and brain development. Lipids 2001;36:885-95. https://doi.org/10.1007/s11745-001-0798-1
  56. Uauy R, Mena P, Rojas C. Essential fatty acids in early life: structural and functional role. Proc Nutr Soc 2000;59:3-15. https://doi.org/10.1017/S0029665100000021
  57. Carlson SE, Colombo J. Docosahexaenoic acid and arachidonic acid nutrition in early development. Adv Pediatr 2016;63:453-71. https://doi.org/10.1016/j.yapd.2016.04.011
  58. Makrides M, Gibson RA. Long-chain polyunsaturated fatty acid requirements during pregnancy and lactation. Am J Clin Nutr 2000;71:307S-311S. https://doi.org/10.1093/ajcn/71.1.307S
  59. Sattar N, Berry C, Greer IA. Essential fatty acids in relation to pregnancy complications and fetal development. Br J Obstet Gynaecol 1998;105:1248-55. https://doi.org/10.1111/j.1471-0528.1998.tb10002.x
  60. Cansev M, Wurtman RJ, Sakamoto T, Ulus IH. Oral administration of circulating precursors for membrane phosphatides can promote the synthesis of new brain synapses. Alzheimers Dement 2008;4:S153-68. https://doi.org/10.1016/j.jalz.2007.10.005
  61. Beltz BS, Tlusty MF, Benton JL, Sandeman DC. Omega-3 fatty acids upregulate adult neurogenesis. Neurosci Lett 2007;415:154-8. https://doi.org/10.1016/j.neulet.2007.01.010
  62. Kawakita E, Hashimoto M, Shido O. Docosahexaenoic acid promotes neurogenesis in vitro and in vivo. Neuroscience 2006;139:991-7. https://doi.org/10.1016/j.neuroscience.2006.01.021
  63. Cutuli D. Functional and structural benefits induced by omega-3 polyunsaturated fatty acids during aging. Curr Neuropharmacol 2017;15:534-42. https://doi.org/10.2174/1570159X14666160614091311
  64. Aryal S, Hussain S, Drevon CA, Nagelhus E, Hvalby O, Jensen V, Walaas SI, Davanger S. Omega-3 fatty acids regulate plasticity in distinct hippocampal glutamatergic synapses. Eur J Neurosci 2019;49:40-50. https://doi.org/10.1111/ejn.14224
  65. Castro-Gomez P, Garcia-Serrano A, Visioli F, Fontecha J. Relevance of dietary glycerophospholipids and sphingolipids to human health. Prostaglandins Leukot Essent Fatty Acids 2015;101:41-51. https://doi.org/10.1016/j.plefa.2015.07.004
  66. Cardoso C, Afonso C, Bandarra NM. Dietary DHA and health: cognitive function ageing. Nutr Res Rev 2016;29:281-94. https://doi.org/10.1017/S0954422416000184
  67. Calviello G, Su HM, Weylandt KH, Fasano E, Serini S, Cittadini A. Experimental evidence of ω-3 polyunsaturated fatty acid modulation of inflammatory cytokines and bioactive lipid mediators: their potential role in inflammatory, neurodegenerative, and neoplastic diseases. Biomed Res Int 2013;2013:743171. https://doi.org/10.1155/2013/743171
  68. Moore K, Hughes CF, Ward M, Hoey L, McNulty H. Diet, nutrition and the ageing brain: current evidence and new directions. Proc Nutr Soc 2018;77:152-63. https://doi.org/10.1017/S0029665117004177
  69. Yassine HN, Braskie MN, Mack WJ, Castor KJ, Fonteh AN, Schneider LS, Harrington MG, Chui HC. Association of docosahexaenoic acid supplementation with Alzheimer disease stage in apolipoprotein E ε4 carriers: a review. JAMA Neurol 2017;74:339-47. https://doi.org/10.1001/jamaneurol.2016.4899
  70. Butler M, Nelson VA, Davila H, Ratner E, Fink HA, Hemmy LS, McCarten JR, Barclay TR, Brasure M, Kane RL. Over-the-counter supplement interventions to prevent cognitive decline, mild cognitive impairment, and clinical Alzheimer-type dementia: a systematic review. Ann Intern Med 2018;168:52-62. https://doi.org/10.7326/m17-1530
  71. Burckhardt M, Herke M, Wustmann T, Watzke S, Langer G, Fink A. Omega-3 fatty acids for the treatment of dementia. Cochrane Database Syst Rev 2016;4:CD009002.
  72. Dangour AD, Whitehouse PJ, Rafferty K, Mitchell SA, Smith L, Hawkesworth S, Vellas B. B-vitamins and fatty acids in the prevention and treatment of Alzheimer's disease and dementia: a systematic review. J Alzheimers Dis 2010;22:205-24. https://doi.org/10.3233/JAD-2010-090940
  73. Sydenham E, Dangour AD, Lim WS. Omega 3 fatty acid for the prevention of cognitive decline and dementia. Cochrane Database Syst Rev 2012;6:CD005379.
  74. Chew EY, Clemons TE, Agron E, Launer LJ, Grodstein F, Bernstein PSAge-Related Eye Disease Study 2 (AREDS2) Research Group. Effect of omega-3 fatty acids, lutein/zeaxanthin, or other nutrient supplementation on cognitive function: the AREDS2 randomized clinical trial. JAMA 2015;314:791-801. https://doi.org/10.1001/jama.2015.9677
  75. Tully AM, Roche HM, Doyle R, Fallon C, Bruce I, Lawlor B, Coakley D, Gibney MJ. Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer's disease: a case-control study. Br J Nutr 2003;89:483-9. https://doi.org/10.1079/BJN2002804
  76. Yassine HN, Feng Q, Azizkhanian I, Rawat V, Castor K, Fonteh AN, Harrington MG, Zheng L, Reed BR, DeCarli C, Jagust WJ, Chui HC. Association of serum docosahexaenoic acid with cerebral amyloidosis. JAMA Neurol 2016;73:1208-16. https://doi.org/10.1001/jamaneurol.2016.1924
  77. van Gelder BM, Tijhuis M, Kalmijn S, Kromhout D. Fish consumption, n-3 fatty acids, and subsequent 5-y cognitive decline in elderly men: the Zutphen Elderly Study. Am J Clin Nutr 2007;85:1142-7. https://doi.org/10.1093/ajcn/85.4.1142
  78. Kalmijn S, Launer LJ, Ott A, Witteman JC, Hofman A, Breteler MM. Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Ann Neurol 1997;42:776-82. https://doi.org/10.1002/ana.410420514
  79. Engelhart MJ, Geerlings MI, Ruitenberg A, Van Swieten JC, Hofman A, Witteman JC, Breteler MM. Diet and risk of dementia: Does fat matter?: the Rotterdam Study. Neurology 2002;59:1915-21. https://doi.org/10.1212/01.WNL.0000038345.77753.46
  80. Pottala JV, Yaffe K, Robinson JG, Espeland MA, Wallace R, Harris WS. Higher RBC EPA + DHA corresponds with larger total brain and hippocampal volumes: WHIMS-MRI study. Neurology 2014;82:435-42. https://doi.org/10.1212/WNL.0000000000000080
  81. Tan ZS, Harris WS, Beiser AS, Au R, Himali JJ, Debette S, Pikula A, Decarli C, Wolf PA, Vasan RS, Robins SJ, Seshadri S. Red blood cell ω-3 fatty acid levels and markers of accelerated brain aging. Neurology 2012;78:658-64. https://doi.org/10.1212/WNL.0b013e318249f6a9
  82. Zhang Y, Chen J, Qiu J, Li Y, Wang J, Jiao J. Intakes of fish and polyunsaturated fatty acids and mild-to-severe cognitive impairment risks: a dose-response meta-analysis of 21 cohort studies. Am J Clin Nutr 2016;103:330-40. https://doi.org/10.3945/ajcn.115.124081
  83. Dangour AD, Allen E, Elbourne D, Fasey N, Fletcher AE, Hardy P, Holder GE, Knight R, Letley L, Richards M, Uauy R. Effect of 2-y n-3 long-chain polyunsaturated fatty acid supplementation on cognitive function in older people: a randomized, double-blind, controlled trial. Am J Clin Nutr 2010;91:1725-32. https://doi.org/10.3945/ajcn.2009.29121
  84. Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, Van Dyck C, Galvin JE, Emond J, Jack CR Jr, Weiner M, Shinto L, Aisen PS. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA 2010;304:1903-11. https://doi.org/10.1001/jama.2010.1510
  85. Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, Basun H, Faxen-Irving G, Garlind A, Vedin I, Vessby B, Wahlund LO, Palmblad J. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol 2006;63:1402-8. https://doi.org/10.1001/archneur.63.10.1402
  86. Lee LK, Shahar S, Chin AV, Yusoff NA. Docosahexaenoic acid-concentrated fish oil supplementation in subjects with mild cognitive impairment (MCI): a 12-month randomised, double-blind, placebocontrolled trial. Psychopharmacology (Berl) 2013;225:605-12. https://doi.org/10.1007/s00213-012-2848-0
  87. Jiao J, Li Q, Chu J, Zeng W, Yang M, Zhu S. Effect of n-3 PUFA supplementation on cognitive function throughout the life span from infancy to old age: a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr 2014;100:1422-36. https://doi.org/10.3945/ajcn.114.095315
  88. Yurko-Mauro K, Alexander DD, Van Elswyk ME. Docosahexaenoic acid and adult memory: a systematic review and meta-analysis. PLoS One 2015;10:e0120391. https://doi.org/10.1371/journal.pone.0120391
  89. Mazereeuw G, Lanctot KL, Chau SA, Swardfager W, Herrmann N. Effects of ω-3 fatty acids on cognitive performance: a meta-analysis. Neurobiol Aging 2012;33:1482.e17-29. https://doi.org/10.1016/j.neurobiolaging.2011.12.014
  90. Avallone R, Vitale G, Bertolotti M. Omega-3 fatty acids and neurodegenerative diseases: new evidence in clinical trials. Int J Mol Sci 2019;20:4256. https://doi.org/10.3390/ijms20174256
  91. Belmaker RH, Agam G. Major depressive disorder. N Engl J Med 2008;358:55-68. https://doi.org/10.1056/NEJMra073096
  92. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997;349:1436-42. https://doi.org/10.1016/S0140-6736(96)07495-8
  93. Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JP, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JP, Geddes JR. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 2018;391:1357-66. https://doi.org/10.1016/S0140-6736(17)32802-7
  94. Hibbeln JR, Nieminen LR, Blasbalg TL, Riggs JA, Lands WE. Healthy intakes of n-3 and n-6 fatty acids: estimations considering worldwide diversity. Am J Clin Nutr 2006;83:1483S-1493S. https://doi.org/10.1093/ajcn/83.6.1483S
  95. Connor WE. Importance of n-3 fatty acids in health and disease. Am J Clin Nutr 2000;71:171S-175S. https://doi.org/10.1093/ajcn/71.1.171S
  96. Su KP. Biological mechanism of antidepressant effect of omega-3 fatty acids: how does fish oil act as a 'mind-body interface'? Neurosignals 2009;17:144-52. https://doi.org/10.1159/000198167
  97. Su KP, Shen WW, Huang SY. Effects of polyunsaturated fatty acids on psychiatric disorders. Am J Clin Nutr 2000;72:1241. https://doi.org/10.1093/ajcn/72.5.1241
  98. Lin PY, Huang SY, Su KP. A meta-analytic review of polyunsaturated fatty acid compositions in patients with depression. Biol Psychiatry 2010;68:140-7. https://doi.org/10.1016/j.biopsych.2010.03.018
  99. Hibbeln JR. Fish consumption and major depression. Lancet 1998;351:1213. https://doi.org/10.1016/S0140-6736(05)79168-6
  100. Nemets B, Stahl Z, Belmaker RH. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry 2002;159:477-9. https://doi.org/10.1176/appi.ajp.159.3.477
  101. Peet M, Horrobin DF. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry 2002;59:913-9. https://doi.org/10.1001/archpsyc.59.10.913
  102. Su KP, Huang SY, Chiu CC, Shen WW. Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. Eur Neuropsychopharmacol 2003;13:267-71. https://doi.org/10.1016/S0924-977X(03)00032-4
  103. Jazayeri S, Tehrani-Doost M, Keshavarz SA, Hosseini M, Djazayery A, Amini H, Jalali M, Peet M. Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder. Aust N Z J Psychiatry 2008;42:192-8. https://doi.org/10.1080/00048670701827275
  104. Su KP, Huang SY, Chiu TH, Huang KC, Huang CL, Chang HC, Pariante CM. Omega-3 fatty acids for major depressive disorder during pregnancy: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2008;69:644-51. https://doi.org/10.4088/JCP.v69n0418
  105. Frangou S, Lewis M, McCrone P. Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study. Br J Psychiatry 2006;188:46-50. https://doi.org/10.1192/bjp.188.1.46
  106. da Silva TM, Munhoz RP, Alvarez C, Naliwaiko K, Kiss A, Andreatini R, Ferraz AC. Depression in Parkinson's disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation. J Affect Disord 2008;111:351-9. https://doi.org/10.1016/j.jad.2008.03.008
  107. Mischoulon D, Papakostas GI, Dording CM, Farabaugh AH, Sonawalla SB, Agoston AM, Smith J, Beaumont EC, Dahan LE, Alpert JE, Nierenberg AA, Fava M. A double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive disorder. J Clin Psychiatry 2009;70:1636-44. https://doi.org/10.4088/JCP.08m04603
  108. Rapaport MH, Nierenberg AA, Schettler PJ, Kinkead B, Cardoos A, Walker R, Mischoulon D. Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study. Mol Psychiatry 2016;21:71-9. https://doi.org/10.1038/mp.2015.22
  109. Lesperance F, Frasure-Smith N, St-Andre E, Turecki G, Lesperance P, Wisniewski SR. The efficacy of omega-3 supplementation for major depression: a randomized controlled trial. J Clin Psychiatry 2011;72:1054-62. https://doi.org/10.4088/JCP.10m05966blu
  110. Gertsik L, Poland RE, Bresee C, Rapaport MH. Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder. J Clin Psychopharmacol 2012;32:61-4. https://doi.org/10.1097/JCP.0b013e31823f3b5f
  111. Martins JG. EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: evidence from a meta-analysis of randomized controlled trials. J Am Coll Nutr 2009;28:525-42. https://doi.org/10.1080/07315724.2009.10719785
  112. Bloch MH, Hannestad J. Omega-3 fatty acids for the treatment of depression: systematic review and metaanalysis. Mol Psychiatry 2012;17:1272-82. https://doi.org/10.1038/mp.2011.100
  113. Martins JG, Bentsen H, Puri BK. Eicosapentaenoic acid appears to be the key omega-3 fatty acid component associated with efficacy in major depressive disorder: a critique of Bloch and Hannestad and updated meta-analysis. Mol Psychiatry 2012;17:1144-9. https://doi.org/10.1038/mp.2012.25
  114. Grosso G, Pajak A, Marventano S, Castellano S, Galvano F, Bucolo C, Drago F, Caraci F. Role of omega-3 fatty acids in the treatment of depressive disorders: a comprehensive meta-analysis of randomized clinical trials. PLoS One 2014;9:e96905. https://doi.org/10.1371/journal.pone.0096905
  115. Mocking RJ, Harmsen I, Assies J, Koeter MW, Ruhe HG, Schene AH. Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder. Transl Psychiatry 2016;6:e756. https://doi.org/10.1038/tp.2016.29
  116. Bai ZG, Bo A, Wu SJ, Gai QY, Chi I. Omega-3 polyunsaturated fatty acids and reduction of depressive symptoms in older adults: a systematic review and meta-analysis. J Affect Disord 2018;241:241-8. https://doi.org/10.1016/j.jad.2018.07.057
  117. Hallahan B, Ryan T, Hibbeln JR, Murray IT, Glynn S, Ramsden CE, SanGiovanni JP, Davis JM. Efficacy of omega-3 highly unsaturated fatty acids in the treatment of depression. Br J Psychiatry 2016;209:192-201. https://doi.org/10.1192/bjp.bp.114.160242
  118. Lin PY, Su KP. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J Clin Psychiatry 2007;68:1056-61. https://doi.org/10.4088/JCP.v68n0712
  119. Lin PY, Mischoulon D, Freeman MP, Matsuoka Y, Hibbeln J, Belmaker RH, Su KP. Are omega-3 fatty acids antidepressants or just mood-improving agents? The effect depends upon diagnosis, supplement preparation, and severity of depression. Mol Psychiatry 2012;17:1161-3. https://doi.org/10.1038/mp.2012.111
  120. Appleton KM, Sallis HM, Perry R, Ness AR, Churchill R. Omega-3 fatty acids for depression in adults. Cochrane Database Syst Rev 2015;2015:CD004692.
  121. Su KP, Wang SM, Pae CU. Omega-3 polyunsaturated fatty acids for major depressive disorder. Expert Opin Investig Drugs 2013;22:1519-34. https://doi.org/10.1517/13543784.2013.836487
  122. Su KP. Personalized medicine with Omega-3 fatty acids for depression in children and pregnant women and depression associated with inflammation. J Clin Psychiatry 2015;76:e1476-7. https://doi.org/10.4088/jcp.15l10011
  123. Chang CH, Tseng PT, Chen NY, Lin PC, Lin PY, Chang JP, Kuo FY, Lin J, Wu MC, Su KP. Safety and tolerability of prescription omega-3 fatty acids: a systematic review and meta-analysis of randomized controlled trials. Prostaglandins Leukot Essent Fatty Acids 2018;129:1-12. https://doi.org/10.1016/j.plefa.2018.01.001
  124. Su KP. Nutrition, psychoneuroimmunology and depression: the therapeutic implications of omega-3 fatty acids in interferon-α-induced depression. Biomedicine (Taipei) 2015;5:21. https://doi.org/10.7603/s40681-015-0021-x
  125. Song C, Shieh CH, Wu YS, Kalueff A, Gaikwad S, Su KP. The role of omega-3 polyunsaturated fatty acids eicosapentaenoic and docosahexaenoic acids in the treatment of major depression and Alzheimer's disease: acting separately or synergistically? Prog Lipid Res 2016;62:41-54. https://doi.org/10.1016/j.plipres.2015.12.003
  126. Li F, Liu X, Zhang D. Fish consumption and risk of depression: a meta-analysis. J Epidemiol Community Health 2016;70:299-304. https://doi.org/10.1136/jech-2015-206278
  127. Liao Y, Xie B, Zhang H, He Q, Guo L, Subramaniapillai M, Fan B, Lu C, Mclntyer RS. Efficacy of omega-3 PUFAs in depression: a meta-analysis. Transl Psychiatry 2019;9:190. https://doi.org/10.1038/s41398-019-0515-5
  128. Guu TW, Mischoulon D, Sarris J, Hibbeln J, McNamara RK, Hamazaki K, Freeman MP, Maes M, Matsuoka YJ, Belmaker RH, Jacka F, Pariante C, Berk M, Marx W, Su KP. International Society for Nutritional Psychiatry Research Practice Guidelines for omega-3 fatty acids in the treatment of major depressive disorder. Psychother Psychosom 2019;88:263-73. https://doi.org/10.1159/000502652
  129. Larque E, Gil-Sanchez A, Prieto-Sanchez MT, Koletzko B. Omega 3 fatty acids, gestation and pregnancy outcomes. Br J Nutr 2012;107 Suppl 2:S77-84. https://doi.org/10.1017/S0007114512001481
  130. Makrides M, Gibson RA, McPhee AJ, Yelland L, Quinlivan J, Ryan P, DOMInO Investigative Team. Effect of DHA supplementation during pregnancy on maternal depression and neurodevelopment of young children: a randomized controlled trial. JAMA 2010;304:1675-83. https://doi.org/10.1001/jama.2010.1507
  131. Carlson SE, Colombo J, Gajewski BJ, Gustafson KM, Mundy D, Yeast J, Georgieff MK, Markley LA, Kerling EH, Shaddy DJ. DHA supplementation and pregnancy outcomes. Am J Clin Nutr 2013;97:808-15. https://doi.org/10.3945/ajcn.112.050021
  132. Shireman TI, Kerling EH, Gajewski BJ, Colombo J, Carlson SE. Docosahexaenoic acid supplementation (DHA) and the return on investment for pregnancy outcomes. Prostaglandins Leukot Essent Fatty Acids 2016;111:8-10. https://doi.org/10.1016/j.plefa.2016.05.008
  133. de Seymour JV, Simmonds LA, Gould J, Makrides M, Middleton P. Omega-3 fatty acids to prevent preterm birth: Australian pregnant women's preterm birth awareness and intentions to increase omega-3 fatty acid intake. Nutr J 2019;18:74. https://doi.org/10.1186/s12937-019-0499-2
  134. Koletzko B, Poindexter B, Uauy R. Recommended nutrient intake levels for stable, fully enterally fed very low birth weight infants. World Rev Nutr Diet 2014;110:297-9. https://doi.org/10.1159/000360195

Cited by

  1. Nutritional supplementation of the pharmacotherapy of prostate diseases vol.7, pp.3, 2021, https://doi.org/10.3897/rrpharmacology.7.67465
  2. Using Fecal DNA Metabarcoding to Investigate Foraging Reveals the Effects of Specific Herbage on the Improved n-3 Fatty Acid (PUFA) Composition in the Longissimus Dorsi Muscle of Grazing Tan Sheep vol.69, pp.33, 2021, https://doi.org/10.1021/acs.jafc.1c03788
  3. Russian Society for the Prevention of Noncommunicable Diseases (ROPNIZ). Alimentary-dependent risk factors for chronic non-communicable diseases and eating habits: dietary correction within the framew vol.20, pp.5, 2021, https://doi.org/10.15829/1728-8800-2021-2952
  4. Can Fish and Shellfish Species from the Black Sea Supply Health Beneficial Amounts of Bioactive Fatty Acids? vol.11, pp.11, 2021, https://doi.org/10.3390/biom11111661
  5. Key Targets for Improving Algal Biofuel Production vol.3, pp.4, 2021, https://doi.org/10.3390/cleantechnol3040043
  6. Fatty acids in normal and pathological pregnancies vol.539, 2022, https://doi.org/10.1016/j.mce.2021.111466
  7. Sustainable oil-based ingredients with health benefits for food colloids and products vol.43, 2021, https://doi.org/10.1016/j.cofs.2021.10.004